Thirty healthy volunteers were recruited into a study to determine the effects on the gastrointestinal mucosa of 3 different delivery systems of oral potassium supplementation associated with diuretic therapy (Diumide-K ContinusR tablets, Napp; Lasikal tablets, Hoechst; Lasix and Slow-KR tablets, Hoechst, Ciba). The volunteers *were gastroscoped initially and after one week of treatment with one of the three therapies. There was a '60% incidence of erosions in the Lasix + Slow-K group, a 40% incidence in the Lasikal group, but no erosions in the group receiving Diumide-K Continus tablets. It is therefore concluded that Diumide-K Continus tablets incorporate the potassium in a delivery system which is unlikely to cause disruption to the gatrointestinal mucosa.
Introduction
Over 1.7 million prescriptions a year in the UK are written for potassium supplements to diuretic therapy. Until recently, the most widely used preparation in the UK has been a wax matrix slow-release tablet, Slow-KR (Ciba; potassium chloride 600 mg, 8 mEq), which was thought to be safe, and replaced the earlier enteric-coated tablets which were shown to produce gastrointestinal ulceration, haemorrhage and obstruction (Allen et al. 1965 , Lawrason et al. 1965 . However, in recent years there have been an increasing number of reports from many countries of the wax matrix tablets causing gastrointestinal ulceration (Farquharson-Roberts et al. 1975 , McCall 1975 , McAvoy 1974 , McMahon & Akdamar 1976 , Weiss et al. 1977 , McMahon et al. 1983 , Lubbe et al. 1979 , Dayer et al. 1977 , particularly if the gastrointestinal tract is obstructed or even if motility is slightly impeded (McMahon & Akdamar 1976 , Weiss et al. 1977 , Lowry et al. 1975 .
A combined tablet of frusemide (40 mg) and controlled-release potassium chloride (600 mg, 8 mEq) (Diumide-K ContinusR; Napp) is widely prescribed in this hospital, and because of these potential problems it was decided to investigate the effects of these tablets on the gastric mucosa. A study undertaken in 20 healthy volunteers who took one tablet daily for seven days, and who were gastroscoped before and after treatment, demonstrated no erosions or even inflammation (McLoughlin 1984) . These results contrasted markedly with the methodologically similar study carried out by McMahon et al. (1983) which demonstrated a 55% incidence of erosions after a week of therapy with wax matrix KCI tablets. A more controlled study was therefore carried out comparing Diumide-K with both wax matrix KCI tablets and another more recently available combined tablet, Lasikal (frusemide 20 mg and potassium chloride 750 mg, 10 mEq; Hoechst).
Methods
Thirty-seven healthy volunteers (mean age 25 87 years, range 17-50 years) with no symptoms of gastrointestinal disease gave their written informed consent, underwent an initial gastroscopic examination and were graded as shown in Table 1 . At this stage 7 subjects (6 male, 1 female) were found to be Grade 3 or above and were excluded. The remaining 30 (17 female, 13 male) were found to be suitable (Grade 2 or below) and were recruited into the study. Apart from being told to avoid alcohol, salicylates and other non-steroidal anti-inflammatory drugs 1Accepted 13 December 1984 2Present address: Mater Infirmorum Hospital, Belfast Erosions, numerous (> 3) 4 Ulceration, single 5
Multiple ulcerations (> 1) during the study period, the subjects were told to continue with their normal diet and fluid intake. They were randomly allocated to one of three treatment groups: Group 1 -one Diumide-K ContinusR tablet daily; Group 2-two Lasikal tablets daily; Group 3-one frusemide 40 mg (Lasix) +two Slow-K tablets daily. (These dosages were chosen as they represent the most commonly prescribed daily dose of frusemide, i.e. 40 mg, with the recommended potassium supplementation.) Seven days later all subjects returned for a second gastroscopic examination.
Gastroscopy: Some subjects attended in the morning after fasting overnight and some attended during the afternoon having eaten nothing after a light breakfast at 8 am. All were premedicated with an intravenous injection of 10 mg papaveretum and 0-2 mg/ml hyoscine hydrobromide (Omnopon-Scopolamine; Roche) one hour before the procedure and were then given intravenous diazepam (Diazemuls; KabiVitrum), immediately prior to the procedure, sufficient to sedate them to the usual point of ptosis for gastroscoping. The gastroscope used throughout was the Olympus GIF-Q and photographs of the antrum were taken with an Olympus Polaroid EC-3 camera prior to inserting the gastroscope into the duodenum to avoid misinterpretation of the results owing to trauma. The investigator was blind to the allocation of treatment throughout the trial.
Results
There was a marked difference between the groups in the scores for the second gastroscopic examination ( Table 2 ). Only two patients in Group 1 (Diumide-K ContinusR tablets) had an increase in their rating scores (both from 0-1) and one patient actually had a decrease (1-0). In Group 2 (Lasikal tablets) 5 patients increased their rating scores (O-1 = 1, 0-2 = 1, 0-3 = 1, 1-2 = 2) and in Group 3 (frusemide + Slow-K tablets) 6 patients increased their rating scores (O-2=2, 0-3= 1, 1-2=2, 1-3= 1); patient number 18 in this group was particularly noteworthy, having 11 visible erosions at this second examination.
There was no significant difference in the ages of the three groups or in the ratio between males and females recruited. Thre was also no significant difference in the ratio between males and females with regard to changes in rating scores. There were 4 reports of minor side effects (1 slight nausea in Group 1, 1 slight constipation in Group 2, 1 vomiting in Group 3 and 1 slight dyspepsia in the Group 2 patient (no. 27) who had 5 small erosions visible at the second gastroscopic examination.
Discussion
The necessity for potassium supplementation in patients on diuretic therapy has been questioned by some investigators (Davidson et al. 1976 , Kassirer & Harrington 1977 , Medical Letter on Drugs and Therapeutics 1981 . However, the diets of elderly patients are often lacking in foods high in potassium (Judge 1972 , Davies et al. 1973 , British Medical Journal 1978 , Lancet 1974 and the importance -of preventing hypokalaemiaparticularly in patients taking digitalis, who often already have reduced body potassium because of their heart failure (Flear 1969 , Nagant de Deux Chaisnes & Mach 1974 , Cohen 1979 )-is well recognized (Dyckner et al. 1975 , Spector 1972 , Lant 1977 , British Medical Journal 1977 , McCarthy 1983 .
The wax matrix KC1 tablets that are widely prescribed in many countries throughout the world have been shown to cause gastrointestinal ulceration (McMahon & Akdamar 1976 , Weiss et al. 1977 , McMahon et al. 1983 , Dayer et al. 1977 ), mouth ulceration (McAvoy 1974 , small bowel perforation (Farquharson-Roberts et al. 1975) , oesophageal ulceration, particularly if motility is even slightly impaired (McCall 1975 , Lubbe et al. 1979 , Lowry et al. 1975 , Rosenthal et al. 1974 , and perforation of the oesophagus secondary to ulceration and penetration into the aorta (McCall 1975 , Rosenthal et al. 1974 .
In a previous study in this centre it was shown that the KC1 contained in the controlledrelease system in Diumide-K ContinusR tablets did not cause erosions or even inflammation (McLoughlin 1984) . This study was methodologically similar to that reported by McMahon et al. (1983) which showed a 55% incidence of gastrointestinal lesions in volunteers after a week of therapy with wax matrix KC1 tablets. In the three treatment groups in the present study, the daily doses of KC1 were different; the preparations were deliberately chosen, however, because they represented the most commonly prescribed daily dose of frusemide (40 mg), with t-he individual manufacturers' recommended dose of KC1 supplementation, and it was felt that this would reflect normal clinical practice.
The results clearly show that there is a very marked difference between the groups. The wax matrix KC1 tablets produced a 60% incidence of erosions, closely matching the findings of McMahon et al. (1983) , and the Lasikal group also produced a high incidence of erosions (40%). This contrasts sharply with the group taking Diumide-K Continus tablets, where there were no erosions and only 2 cases of mild hyperaemia. It could be argued that one reason for the lack of side effects in this group is that KC1 is not absorbed, but two recent studies have demonstrated that serum potassium levels are maintained or even increased when compared with separate KC1 tablet therapy (Lewis 1979 , Rao 1982 , so this is obviously not the case. It would appear, therefore, that the-controlled, predictable release of potassium by the Continus mechanism used in the Diumide-K tablet protects the gastrointestinal mucosa from the potentially erosive potassium ions. Further work in this area is being carried out in this centre incorporating an anticholinergic agent to slow gastrointestinal transit times.
